{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:01:31Z","timestamp":1790226091494,"version":"4.1.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non-cryopreserved hematopoietic stem cells (NCP HSCs) may simplify autologous stem cell transplantation (ASCT) by avoiding cryopreservation and dimethyl sulfoxide exposure. We compared the clinical outcomes of NCP HSCs and cryopreserved HSCs (CP HSCs) in patients with multiple myeloma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective, single-center cohort study included 200 consecutive patients with multiple myeloma who underwent ASCT between 2014 and 2024: 147 received NCP HSCs, and 53 received CP HSCs. Preservation practices changed over time, and NCP HSC use increased from 46.6% during 2014\u20132019 to 94.6% during 2020\u20132024. The baseline characteristics were not fully balanced: patients receiving NCP HSCs were older (mean age 59.0 vs. 56.5 years), and bortezomib\u2013thalidomide\u2013dexamethasone (VTD) induction was more frequent in the NCP HSC group, whereas cyclophosphamide\u2013thalidomide\u2013dexamethasone (CTD) predominated in the CP HSC group, and the infused CD34\n                      <jats:sup>+<\/jats:sup>\n                      cell dose was higher with NCP HSCs. Sex and myeloma subtype were comparable between the groups, while pre-transplant disease response differed significantly between the cohorts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median time to engraftment was 12 days [interquartile range (IQR), 11\u201313; range, 9\u201324] with NCP HSCs and 12 days (IQR, 11\u201314; range, 10\u201322) with CP HSCs (Mann\u2013Whitney U\u00a0=\u00a03239, p = 0.062). Median hospitalization was shorter with NCP HSCs [17 days (IQR, 14\u201320)] than with CP HSCs [23.5 days (IQR, 18\u201326); p &amp;lt; 0.001]. Transplant-related mortality was 3.4% and 5.7% (p = 0.528), and overall survival was comparable. Mucositis was more frequent in the NCP HSC group, whereas infectious complications did not differ significantly. In multivariable Cox analysis, the stem cell preservation method was not independently associated with progression-free survival (PFS) (adjusted HR, 1.44; 95% CI, 0.76\u20132.74; p = 0.262). Pre-transplant very good partial response (VGPR) compared with complete response (CR) was associated with a higher progression hazard (adjusted HR, 1.83; 95% CI, 1.10\u20133.04; p = 0.020), whereas maintenance therapy was associated with a lower progression hazard (adjusted HR, 0.48; 95% CI, 0.26\u20130.89; p = 0.020).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with CP HSC transplantation, NCP HSC transplantation provided comparable engraftment, transplant-related mortality, and overall survival and was associated with shorter hospitalization. Although PFS differed between the cohorts, multivariable analysis did not identify the stem cell preservation method as an independent predictor of PFS. These findings support NCP HSC transplantation as a feasible alternative when appropriate logistical conditions are available, while emphasizing the contribution of disease- and treatment-related factors to long-term outcomes. NCP HSCs represent an alternative for ASCT in multiple myeloma, although the retrospective design, temporal changes in practice, and baseline differences between the cohorts limit causal interpretation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1955153","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:34:44Z","timestamp":1790224484000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of non-cryopreserved and cryopreserved autologous hematopoietic stem cell transplantation among patients with myeloma: single-center experience"],"prefix":"10.3389","volume":"16","author":[{"given":"Lazar","family":"Chadievski","sequence":"first","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milche","family":"Cvetanoski","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Genadieva Stavrikj","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlate","family":"Stojanoski","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija","family":"Popova Labacevska","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dusko","family":"Dukovski","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Trajkova","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Purde","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Stojanoski","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivera","family":"Gjeorgjieva Janev","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arita","family":"Fazliu","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Pivkova Veljanovska","sequence":"additional","affiliation":[{"name":"University Clinic for Hematology","place":["Skopje, North Macedonia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","unstructured":"Seer: Surveillance Epidemiology & End Results"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.18103\/mra.v13i12.7088","article-title":"Epidemiology, risk factors, and prevention strategies of multiple myeloma cancer: a systematic review","volume":"13","author":"Lawanson","year":"2025","journal-title":"Med Res Arch"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification and management","volume":"99","author":"Rajkumar","year":"","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.23736\/s0031-0808.20.04114-2","article-title":"Autologous stem cell transplantation in multiple myeloma","volume":"62","author":"Ricciuti","year":"2020","journal-title":"Panminerva Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/trf.14072","article-title":"Adverse events of cryopreserved hematopoietic stem cell infusions in adults: a single-center observational study","volume":"57","author":"Otrock","year":"2017","journal-title":"Transfusion"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1182\/blood-2019-132261","article-title":"Viability of stem cells without cryopreservation: How good and how long","volume":"134","author":"Khine","year":"2019","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra052638","article-title":"Hematopoietic stem-cell transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cir073","article-title":"Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America","volume":"52","author":"Freifeld","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-44080-9_16","article-title":"Mobilization and collection of hematopoietic stem cells","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Worel","year":"2024"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.10.017","article-title":"Correlation of engraftment and time from melphalan administration to stem-cell infusion","volume":"29","author":"Shuman","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-031-44080-9_6","article-title":"Statistical methods in HCT and cellular therapies","volume-title":"The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies","author":"Iacobelli","year":"2024"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-018-0117-5","article-title":"Advantages of non-cryopreserved autologous hematopoietic stem cell transplantation against a cryopreserved strategy","volume":"53","author":"Sarmiento","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.08.007","article-title":"Use of non-cryopreserved peripheral blood stem cells is associated with adequate engraftment in patients with multiple myeloma undergoing an autologous transplant","volume":"24","author":"Kulkarni","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.12659\/AOT.927084","article-title":"Outcomes of non-cryopreserved versus cryopreserved peripheral blood stem cells for autologous stem cell transplantation in multiple myeloma","volume":"25","author":"Piriyakhuntorn","year":"2020","journal-title":"Ann Transplant"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-022-01718-2","article-title":"Cryopreserved versus non-cryopreserved stem cell autografts in multiple myeloma: a retrospective cohort study","volume":"57","author":"Pessoa","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/trf.17090","article-title":"Non-cryopreserved peripheral blood stem cells as a safe and effective alternative for autologous transplantation in multiple myeloma","volume":"62","author":"Ara\u00fajo","year":"2022","journal-title":"Transfusion"},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41409-024-02431-y","article-title":"Non-cryopreserved autologous peripheral blood stem cell transplantation for multiple myeloma and lymphoma in countries with limited resources: practice considerations from the Worldwide Network for Blood and Marrow Transplantation","volume":"60","author":"Bekadja","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2026.104493","article-title":"Non-cryopreserved hematopoietic stem cell transplantation compared to conventional autologous peripheral stem cell transplantation with cryopreserved stem cells among patients newly diagnosed with myeloma","volume":"65","author":"Vural","year":"2026","journal-title":"Transfus Apher Sci"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S616716","article-title":"Cryopreserved versus fresh stem cell grafts in autologous transplantation for multiple myeloma: impact on early toxicity and engraftment","volume":"17","author":"Sarmiento","year":"2026","journal-title":"J Blood Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"101906","DOI":"10.1016\/j.jcyt.2025.02.008","article-title":"A comparison of cryopreserved and noncryopreserved peripheral blood hematopoietic stem cells for autologous transplantation in multiple myeloma: a study from the Chronic Malignancies Working Party of the EBMT","volume":"28","author":"Bekadja","year":"2026","journal-title":"Cytotherapy"},{"key":"B22","article-title":"Efficacy and safety of autologous transplant with non-cryopreserved peripheral blood stem cells in myeloma and lymphoma in Algeria: 10 years\u2019 experience","volume":"100","author":"Bekadja","year":"2022","journal-title":"Tunis Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1955153\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:35:02Z","timestamp":1790224502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1955153\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1955153"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1955153","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1955153"}}